Adrenal glands in childhood

Childhood is a phase in which the adrenal gland cannot be interpreted as merely a smaller version of the adult organ, because its development accompanies and influences several of the major biological transitions of childhood, from the neonatal period through adrenarche and puberty. In children, adrenal physiology is defined by a dynamic balance between cortical maturation, regulation of the hypothalamic-pituitary-adrenal axis, progressive differentiation of the zona reticularis and the capacity to respond to metabolic, infectious and hemodynamic stress. This makes pediatric adrenal medicine distinctive, because the same hormonal abnormality may present very differently depending on age, sex, developmental stage and the available endocrine reserve.

From a clinical perspective, pediatric adrenal disorders include congenital conditions, genetic disorders of steroidogenesis, primary or central adrenal insufficiency, forms of androgen excess, adrenocortical tumors and catecholamine-related syndromes. In this setting, the challenge is not only to recognize the presence of an endocrine disease, but also to distinguish it from physiological features of growth, such as adrenarche, or from nonspecific manifestations that may be incorrectly attributed to gastrointestinal, nutritional, infectious or behavioral disorders in children. Correct interpretation of the adrenal gland in childhood therefore requires an assessment integrating development, laboratory testing, genetics and the clinical evaluation of growth, because in many conditions the timing of diagnosis substantially changes prognosis, growth, puberty and long-term quality of life.

The pediatric adrenal gland undergoes morphological and functional stages that have no equivalent in adulthood. In the newborn, the cortex still displays the characteristics of the fetal adrenal gland, with a highly developed fetal zone that regresses during the first months after birth. This involution is one of the earliest key events in postnatal endocrine physiology and explains why the steroid profile of a newborn cannot be interpreted using criteria applicable to an older infant or child. During the first years of life, the gland enters a relatively more stable phase, while the subsequent maturation of the zona reticularis prepares the way for the onset of adrenarche.

Differentiation of the zona reticularis is not immediate at birth, but becomes progressively recognizable during childhood and is accompanied by increasing production of DHEA and DHEAS. This process is central because it marks the transition from an adrenal function predominantly directed toward neonatal survival and the stress response to a more complex physiology capable of contributing to pubertal maturation and the peripheral metabolism of androgens. Adrenarche is therefore not a gonadal event, but a specifically adrenal phenomenon that follows its own timeline and is governed by mechanisms that have not yet been fully elucidated at the molecular level.

In children, glucocorticoid and mineralocorticoid function must be interpreted in the context of development. The capacity to produce sufficient cortisol during stress is essential from the neonatal period, while the systems regulating fluid and electrolyte balance are particularly important during the first months of life, when hemodynamic stability depends more heavily on the balance among sodium, water and aldosterone. This explains why adrenal insufficiency or enzyme deficiencies causing salt wasting may present dramatically in infants, whereas the same disorder may emerge with more subtle phenotypes later in life.

Adrenal development is also closely linked to linear growth and bone maturation. Although adrenal androgens have weak intrinsic activity, they are an important source of peripheral precursors and contribute to the appearance of adult-type body odor, seborrhea, axillary and pubic hair and a transient acceleration in growth velocity. In healthy children, this transition follows a relatively predictable chronology; when it occurs excessively early or is unusually pronounced, the possibility of nonphysiological androgen production must be considered.

Pediatric adrenal physiology is therefore closely age-dependent. In newborns, the main issue is hormonal stability and early recognition of the most severe deficiencies; in young children, the focus is on diagnosing congenital forms and the initial manifestations of androgen excess; in older children and adolescents, adrenarche, puberty, hormone-secreting tumors and differentiation from gonadal or pituitary disorders become increasingly important. This continuum makes the adrenal gland one of the most time-dependent endocrine systems of childhood, in which every biological finding acquires meaning only when precisely related to the stage of development.

Finally, adrenal development is not solely a morphological issue, but also a genetic and regulatory one. Many pediatric disorders arise from congenital defects of steroidogenesis, abnormalities in glandular development or altered sensitivity of target tissues. For this reason, adrenal assessment in childhood requires a broader perspective than in adults: it is not sufficient to identify the abnormal hormone; it is also necessary to understand which developmental phase has been disrupted, which compartment of the gland is involved and how this translates into abnormalities of growth, homeostasis and sexual maturation.

Adrenarche is the process through which the zona reticularis acquires the capacity to produce increasing amounts of DHEA and DHEAS, followed by their peripheral conversion into more active androgens. It is a physiological phenomenon of mid-childhood, distinct from gonadal puberty and independent of activation of the hypothalamic-pituitary-gonadal axis. Clinically, adrenarche is reflected by the gradual appearance of pubic or axillary hair, adult-type body odor, a mild increase in sebaceous secretion and, in some cases, modest acceleration of linear growth. Its importance in pediatric endocrinology arises from the fact that, although these signs are often benign, they may also represent the first indication of pathological androgen excess.

The most common form of early adrenarche is premature adrenarche, defined by the early appearance of androgenic signs associated with an increase in adrenal androgens above the values expected for age, after other causes have been excluded. The condition is more common in girls than in boys and often follows a benign course, but it should not be dismissed. Premature adrenarche is a diagnosis of exclusion requiring the elimination of nonclassic congenital adrenal hyperplasia, virilizing tumors, central precocious puberty and other causes of hyperandrogenism.

The crucial clinical issue is to distinguish early but physiologically limited maturation from inappropriate androgen production. Physiological adrenarche produces gradual signs, without marked virilization, disproportionate growth relative to genetic target height or rapid advancement of bone age. When clitoromegaly, a marked increase in muscle mass, deepening of the voice, very rapid growth, severe acne or substantial advancement of bone maturation occurs, the condition lies outside the boundaries of normality and requires prompt investigation.

Adrenarche also has metabolic and prognostic implications. Although it represents a variant of normal development for many children, in some individuals it has been associated with greater adiposity, insulin resistance, accelerated bone maturation and, particularly in girls, a potentially increased risk of future metabolic abnormalities or hyperandrogenic syndromes during adolescence. This does not mean that every case of premature adrenarche should be medicalized, but it does imply that management should not end with initial reassurance and that follow-up should consider growth, weight, puberty and the clinical course over time.

The biological rationale underlying adrenarche has not yet been fully clarified. Maturation of the zona reticularis is known to alter the enzymatic pattern of steroidogenesis and promote the production of androgen precursors, but the mechanisms regulating individual timing remain only partially defined. This uncertainty explains why the boundary between normal developmental variability and early disease is sometimes subtle. In practice, the pediatric clinician must consider not only the absolute DHEAS or androstenedione value, but also the growth pattern, bone age, rate of progression of clinical signs and the possible presence of atypical symptoms.

In summary, adrenarche is one of the main examples of how the adrenal gland participates physiologically in pediatric development while remaining potentially ambiguous from a clinical perspective. It is a normal event that may become clinically significant when it occurs too early, is too intense or is associated with findings incompatible with a simple maturational variation. For this reason, adrenal assessment in childhood must always place hormonal findings within the chronology of development, because without this framework even an accurate test result may be interpreted incorrectly.

Pediatric adrenal diagnostics require greater interpretative caution than in adults because hormonal values change with age, sex, pubertal stage and analytical method. A result that appears abnormal may actually fall within the physiology of a specific developmental phase, whereas a borderline value may be pathological when considered in a highly suggestive clinical context. The first practical principle is therefore always to use pediatric reference ranges and, whenever possible, ranges specific to age and pubertal stage.

When adrenal insufficiency is suspected, assessment begins with cortisol and ACTH, but their interpretation must account for circadian rhythm, clinical condition and the patient's age. In uncertain cases, the ACTH stimulation test retains a central role, while sodium, potassium, blood glucose, plasma renin activity and aldosterone help define possible mineralocorticoid involvement. In children, diagnosis must not be delayed excessively when the clinical picture suggests a risk of adrenal crisis, because postponing treatment may have rapid and severe consequences, particularly in infants.

When congenital adrenal hyperplasia or androgen excess is suspected, measurement of 17-hydroxyprogesterone is the most important initial marker, but it must be interpreted particularly carefully in newborns, in whom false-positive results are common, especially in premature infants or children exposed to perinatal stress. Newborn screening programs have therefore improved early diagnosis of classic forms, but often require confirmation through second-tier testing, more detailed steroid profiles and, increasingly, the integration of mass spectrometry methods or genetic analysis.

In children with signs of early adrenarche, the laboratory strategy must be directed toward distinguishing a physiological variant from disease. DHEAS, androstenedione, testosterone, 17-hydroxyprogesterone, gonadotropins and, in some cases, stimulation tests make it possible to distinguish adrenal androgen excess, central precocious puberty and rarer causes such as hormone-secreting tumors. Bone age assessment remains important because it translates the biological effects of steroid excess into growth-related findings and helps identify forms in which progression is too rapid to be considered a benign maturational variant.

For hormone-secreting tumors, biochemical testing must be tailored to the clinical phenotype. A child with rapid virilization, Cushing syndrome or severe hypertension requires targeted assessment of androgens, cortisol, metanephrines or other steroids according to the suspected condition. In childhood, adrenal tumors are often functioning, more frequently than in adults, which explains why attention to endocrine signs is often more useful than the incidental discovery of a mass.

Imaging should follow the clinical question rather than precede it. Ultrasound may have an initial role in selected situations, but magnetic resonance imaging and CT are the principal tools for characterizing the gland and any masses, with indications adjusted for age and the need to limit radiation exposure. At the same time, genetics has become increasingly important because many pediatric forms of adrenal insufficiency, hyperplasia, cortical tumors or paragangliomas have a hereditary basis. Modern adrenal diagnostics in children are therefore not exclusively hormonal, but increasingly multidimensional.

Ultimately, the pediatric diagnostic strategy should be sequential. The clinical problem is defined first, followed by selection of the most informative hormonal tests, with imaging and genetic testing then used when required by the clinical picture. This approach reduces the risk of false alarms, excessively invasive diagnostic pathways and underestimation of severe forms. In children, laboratory findings must never be interpreted in isolation: they acquire meaning only when integrated with growth, pubertal development, phenotype and family history.

Pediatric adrenal insufficiency is a rare but potentially fatal condition that differs from the adult disorder mainly in its etiology and mode of presentation. While autoimmune and acquired causes predominate in adults, hereditary and congenital forms carry much greater weight in childhood. Diagnostic suspicion must therefore remain high from the neonatal period and early childhood, particularly when nonspecific symptoms are associated with electrolyte disturbances, hypoglycemia, poor growth or recurrent crises during intercurrent illnesses.

The distinction between primary and central disease is fundamental. In primary adrenal insufficiency, the defect lies within the adrenal gland and may involve glucocorticoids, mineralocorticoids and androgens; in central adrenal insufficiency, the disorder involves ACTH or CRH and mineralocorticoid deficiency is generally absent. Clinically, hyperpigmentation, hyponatremia, hyperkalemia and marked ACTH elevation suggest a primary form, whereas pallor, hypoglycemia and association with other pituitary deficiencies suggest a central form. However, clinical signs may be subtle in young children, and diagnosis requires close integration of clinical and laboratory findings.

Pediatric primary forms include congenital adrenal hyperplasia, adrenal hypoplasia, adrenoleukodystrophy, rare genetic syndromes and autoimmune insufficiency, which is more typical at older ages. Central forms may result from congenital hypothalamic-pituitary defects, infiltrative diseases, trauma, neoplasms or suppression caused by exogenous glucocorticoids. The latter has increasing relevance in pediatric practice because prolonged use of high-dose systemic, inhaled or topical steroids may reduce axis responsiveness and create significant vulnerability during acute stress or unprotected withdrawal of treatment.

The most feared risk is adrenal crisis. In infants and young children, it may present with vomiting, lethargy, dehydration, hypotension, hypoglycemia, shock and rapidly progressive electrolyte abnormalities. In older children, severe fatigue, abdominal pain, weight loss and circulatory collapse may also occur. The decisive point is that the diagnosis of a crisis is primarily clinical, and treatment with hydrocortisone and volume replacement must not be delayed while awaiting complete confirmation when suspicion is high.

Chronic management requires physiological glucocorticoid replacement and, in primary forms, fludrocortisone and an adequate sodium intake, particularly in infants. However, treatment in children is not simply a scaled-down version of adult therapy. Excessive doses impair growth, body composition and metabolism; insufficient doses expose the child to crises, poor well-being and ACTH overproduction. Follow-up must therefore integrate symptoms, linear growth, weight, blood pressure, electrolytes, plasma renin activity and the clinical course during infections or other forms of stress.

Family education is essential. Parents must understand the sick-day rules, have access to emergency parenteral hydrocortisone, know when to increase the dose during fever, vomiting, trauma or surgery and understand when urgent hospital assessment is required. In childhood, the quality of care largely depends on this shared competence because many crises do not result from failure of baseline treatment, but from failure to recognize the need for stress dosing. Adrenal insufficiency in children is therefore both an endocrine disorder and a disease requiring continuity of care.

Congenital adrenal hyperplasia is the most important group of pediatric adrenal disorders and the paradigmatic model of defects in steroidogenesis. The most common form is 21-hydroxylase deficiency, which accounts for the vast majority of cases, but deficiencies of 11β-hydroxylase, 3β-HSD, StAR, CYP17A1 and other rarer forms also exist. The common mechanism consists of reduced cortisol synthesis, with a compensatory increase in ACTH, cortical hyperplasia and diversion of precursors toward alternative steroid pathways, particularly androgen synthesis. The clinical outcome varies according to the enzyme involved, the severity of the deficiency and the age at presentation.

In classic forms caused by 21-hydroxylase deficiency, the problem is not limited to androgen excess but may also include loss of mineralocorticoids. Newborns may present with a salt-wasting crisis characterized by vomiting, dehydration, hyponatremia, hyperkalemia and shock, while 46,XX girls may have virilization of the external genitalia at birth. In boys, the absence of genital ambiguity may delay suspicion until a crisis occurs, which is why newborn screening has become so important in reducing diagnostic delays and the risk of early death.

Nonclassic forms have a later and more subtle phenotype. They may emerge during childhood or adolescence with early pubarche, acne, accelerated growth, advancement of bone age or, in older girls, signs of hyperandrogenism. The difficulty in these cases is distinguishing a mild enzyme defect from idiopathic premature adrenarche. Measurement of 17-hydroxyprogesterone, particularly following ACTH stimulation in uncertain cases, remains the cornerstone of assessment, although confirmation may require extended steroid profiles and molecular analysis.

Treatment of classic forms requires hydrocortisone replacement and, in salt-wasting forms, fludrocortisone and sodium supplementation. In CAH, however, treatment has a dual objective: replacing the deficient hormone and controlling androgen excess. This balance is particularly delicate in children because excess glucocorticoid treatment suppresses growth and adversely affects body composition, whereas inadequate control promotes virilization, accelerated bone maturation and loss of height potential. Management therefore requires continuous adjustment based on growth, bone age, clinical findings and biochemical markers.

CAH is also a disorder of transition across stages of care. In young children, the main concerns are the risk of crisis and correct replacement therapy; at school age, growth, schooling, physical activity, adherence and prevention of overtreatment become central; during adolescence, puberty, future fertility, body image and quality of life become increasingly important. In addition, selected forms and patients require monitoring for complications such as testicular adrenal rest tumors, poor metabolic control or psychosocial consequences associate with chronic disease.

In summary, congenital adrenal hyperplasia is not merely an enzyme deficiency, but a dynamic condition that accompanies the entire course of development. For this reason, the pediatric model of care must extend far beyond monitoring hormonal measurements: it must integrate endocrinology, genetics, growth assessment, family counselling and preparation for transition to adult care, with the aim of normalizing development as closely as possible to physiological patterns.

Hypercortisolism in childhood is rare, but has particular clinical significance because it directly interferes with growth, puberty, bone metabolism and body composition. Unlike in adults, the combination of weight gain and reduced height velocity is one of the most useful signs suggesting Cushing syndrome in children. This contrast between excess weight and impaired growth has a high discriminatory value because many forms of simple obesity are instead associated with normal or relatively increased stature for age.

The cause may be ACTH-dependent, as in pituitary Cushing disease, or ACTH-independent due to adrenal disease. Pediatric adrenal forms include adenomas, carcinomas, nodular hyperplasias and rare genetic syndromes. The clinical phenotype includes central obesity, facial fullness, hypertension, violaceous striae, skin fragility, delayed puberty or growth arrest, muscle weakness, mood disturbances and osteopenia. The severity of the condition depends not only on the cortisol level, but also on the duration of exposure and the developmental stage at which it occurs.

Diagnosis is often complex because cortisol may be influenced by stress, obesity, depression or pharmacological treatment. Nevertheless, loss of circadian rhythmicity, elevated urinary free cortisol and abnormal suppression tests remain important in children, provided that they are interpreted in experienced centers. A central aspect is always to exclude exposure to exogenous glucocorticoids first, as this is a much more common cause of hypercortisolism than endogenous disease and may result not only from oral or parenteral treatment, but also from high cumulative doses of inhaled, topical or intra-articular steroids.

In children, the effects of hypercortisolism are particularly evident in growth. Excess cortisol antagonizes GH, IGF-1, bone metabolism and protein synthesis, impairing linear growth while promoting fat accumulation and metabolic abnormalities. This dissociation makes growth a true biological indicator of the severity and duration of glucocorticoid exposure. Even after cure, catch-up growth is not always complete, particularly when diagnosis has been delayed or exposure has occurred during a critical phase of development.

Treatment depends on the etiology but generally aims to remove the source of excess hormone production. Surgery is the cornerstone for resectable pituitary or neoplastic forms, while medical treatment may be used in selected cases or as bridging therapy. After correction of hypercortisolism, the child may experience a phase of secondary or contralateral adrenal insufficiency requiring temporary replacement and monitoring. This is particularly important because “curing” Cushing syndrome does not mark the end of the endocrine problem, but rather the beginning of a period of re-equilibration that is often prolonged and clinically delicate.

In childhood, hypercortisolism should therefore be regarded primarily as a developmental disorder rather than solely a metabolic disease. Early recognition is essential not only to reduce cardiovascular or skeletal risk, but also to protect growth, puberty and final height potential. Every child with atypical obesity, reduced height velocity and cushingoid signs should therefore undergo systematic assessment rather than being prematurely reassured that the condition is simply “common obesity.”

Adrenocortical tumors of childhood are rare, but their clinical features differ from those observed in adults. While many adrenal masses in adults are incidentally discovered and nonfunctioning, cortical neoplasms in children are more commonly hormone-secreting and present with a clear endocrine phenotype. In practice, diagnosis often begins with clinical suspicion of virilization, peripheral precocious puberty, Cushing syndrome or a combination of androgen and glucocorticoid excess, rather than with the incidental detection of a mass.

Pediatric adrenocortical carcinoma is exceptionally rare but particularly important because of its aggressiveness and genetic associations, especially with TP53 variants and syndromes such as Li-Fraumeni syndrome. The age at presentation is often young, and many cases occur during the first years of life. Clinical features may include rapidly progressive pubarche, clitoromegaly, penile enlargement, deepening of the voice, accelerated growth, acne, hypertension or signs of hypercortisolism. Mixed secretion of androgens and cortisol is not uncommon and should always raise suspicion of a functioning cortical lesion.

Assessment requires integration of the hormonal profile and imaging. Measurements of androgens, cortisol, steroid precursors and, where appropriate, metanephrines help define the secretory phenotype and exclude a medullary lesion. Magnetic resonance imaging and CT provide anatomical characterization, but imaging findings alone are not sufficient in children because distinguishing an adenoma from a carcinoma may be difficult and must be considered within the clinical, laboratory and pathological context. Suspicion of malignancy increases with large tumor size, marked hormone secretion, rapid growth and signs of invasion.

Noncortical adrenal masses also enter the pediatric differential diagnosis. Neuroblastoma, adrenal hemorrhage and other congenital lesions must be considered in newborns and infants, while medullary or paraganglionic lesions must also be considered in older children. This broadens the problem from endocrinology alone to pediatric oncology and specialist radiology. In all cases, the presence of endocrine signs accelerates the diagnostic pathway because it suggests a functioning lesion with immediate systemic consequences.

Treatment is predominantly surgical, with the aim of achieving complete resection without tumor rupture and with appropriate staging. In localized disease, surgery offers the best chance of cure; in advanced forms, integrated oncological treatment may be required. The endocrine profile must be reassessed after surgery because removal of a hormone-secreting lesion may reveal temporary suppression of the axis or require monitoring of the contralateral adrenal gland and biochemical recurrence.

The most important clinical point is that rapid virilization in a child must never be attributed automatically to a simple pubertal variation. The relative rarity of adrenal tumors does not justify delaying investigation when signs are progressive, marked or accompanied by substantial advancement of bone age. Pediatric adrenocortical tumors are rare but often endocrinologically conspicuous, and this clinical visibility should be used to achieve diagnosis as early as possible.

Pediatric pheochromocytomas and paragangliomas constitute a highly specific subgroup of endocrine neoplasms occurring during childhood and adolescence. Compared with adults, they have a much higher proportion of hereditary, multifocal or metastatic forms and therefore require systematic genetic evaluation. This feature is not an incidental detail, but one of the principal elements distinguishing pediatric catecholamine-related disease: in a child, a PPGL should be regarded as syndromic until proven otherwise.

The clinical presentation is dominated by hypertension, headache, palpitations, sweating, pallor, tremor and sometimes weight loss, although the condition is not always classically paroxysmal. In some children, hypertension is sustained; in others, intermittent episodes of blood pressure variability or recurrent autonomic symptoms predominate. The difficulty is that catecholamine-related symptoms in childhood may initially be interpreted as anxiety, migraine, renal disease or “essential” hypertension, delaying diagnosis of a condition associated with an immediate and genuine cardiovascular risk.

Biochemical diagnosis is based primarily on plasma free metanephrines or fractionated urinary metanephrines, which retain high sensitivity in children. Once catecholamine excess has been confirmed, imaging is used for localization and staging, with magnetic resonance imaging and selected functional techniques chosen according to the clinical context. Since many pediatric forms are hereditary, biochemical and radiological findings should be followed by genetic characterization, not only for the child but also for the family, given the potential implications for counselling and follow-up.

Treatment requires medical preparation with alpha-adrenergic blockade, volume expansion and, only subsequently, possible beta-adrenergic control of tachycardia. This sequence is non-negotiable because reversing the order may worsen vasoconstriction. Surgery is the definitive treatment in most cases, but its timing and operative strategy must be planned in experienced multidisciplinary centers because of the hemodynamic complexity and potential perioperative risk.

In children, follow-up does not end with removal of the lesion. The likelihood of multifocality, recurrence or a new lesion in the context of a hereditary syndrome makes long-term biochemical and radiological monitoring necessary, individualized according to genotype and the natural history of the disease. This is particularly important in adolescents, in whom transition to adult services must not interrupt surveillance but should transform it into a coordinated pathway involving specialist transition centers.

Pediatric catecholamine-related disease demonstrates clearly that the adrenal gland in children is not only an endocrine organ involved in growth, but may also be the site of genetically determined tumors of high clinical complexity. Every child with severe hypertension, recurrent adrenergic symptoms or a suggestive family history must therefore be assessed with great care, without underestimating a rare but potentially life-threatening condition.

The principal aim of treatment for pediatric adrenal disorders is to reproduce normal physiology without compromising growth and development. In children with adrenal insufficiency or CAH, hydrocortisone is the glucocorticoid of choice because it provides replacement that more closely resembles physiological secretion and offers a better safety margin than longer-acting compounds, which may facilitate overtreatment. Dosage must nevertheless be continuously adjusted according to body growth, infections, physical activity and developmental stage, avoiding both inadequate coverage and chronic steroid excess.

In primary salt-wasting forms, treatment is completed with fludrocortisone and, in infants, adequate sodium supplementation. Monitoring cannot be based solely on laboratory values: appropriate replacement is reflected by blood pressure, hydration, well-being, weight gain, serum sodium and renin levels. A common error is to rely exclusively on a numerical result while overlooking the fact that clinical findings and growth remain decisive indicators of therapeutic adequacy in children.

Stress management is an essential component of pediatric care. Fever, gastroenteritis, trauma, surgery and intense physical activity may require a temporary increase in glucocorticoid coverage. Families must have detailed knowledge of the sick-day rules, possess a written plan and be able to administer or arrange intramuscular hydrocortisone in the event of vomiting, collapse or inability to take medication orally. In many cases, the difference between a well-managed chronic disease and a potentially fatal crisis depends precisely on this practical preparation.

In CAH, treatment is additionally complex because glucocorticoids are used both for replacement and to suppress excess ACTH and androgen production. Achieving balance is particularly difficult during childhood and adolescence, when excessive dosing impairs growth and promotes adiposity, while insufficient dosing permits virilization, advanced bone age and inadequate biochemical control. This makes a strategy of continuous dose titration necessary, based on growth assessment, bone age, symptoms and biomarkers.

In other adrenal disorders, pharmacological treatment varies according to etiology. Catecholamine-secreting tumors require adrenergic blockade before surgery; hypercortisolism may require steroidogenesis inhibitors in selected cases; functioning adrenal masses require management that takes metabolic, hemodynamic and oncological risk into account. In all these situations, the same pediatric principle applies: medication should not be prescribed merely to correct an isolated value, but to protect growth, systemic stability and the child's overall development.

The transition from childhood to adolescence also introduces the issue of adherence. Chronic replacement therapy, frequent monitoring, the need to carry emergency medication and the impact on school and sporting activities may become an increasing burden. Management must therefore progressively involve the patient rather than the family alone, promoting autonomy, understanding of the disease and preparation for transition to adult services. In pediatric adrenal disease, correct treatment is essential, but treatment that is understood and shared is what truly reduces long-term risk and complications.

Follow-up of pediatric adrenal disorders cannot be limited to hormonal monitoring because the true clinical outcome is represented by how the child grows, enters puberty, develops autonomy and reaches adulthood. Linear growth is one of the principal longitudinal indicators: reduced growth velocity, excessive acceleration or loss of height potential may reflect overtreatment, uncontrolled androgen excess or hypercortisolism, respectively. Every pediatric endocrine assessment must therefore also include a detailed evaluation of growth.

Puberty represents a second decisive transition. In conditions involving adrenal androgen excess, there is a risk of early peripheral puberty or rapid bone maturation with impairment of final height; in adrenal insufficiency or glucocorticoid overtreatment, delayed puberty or altered body composition may occur. In this context, the adrenal gland interacts with the gonads, pituitary axis, metabolism and psychosocial development, and assessment must therefore be integrated rather than restricted to a single organ.

Body composition and metabolic risk also deserve attention. Children with CAH, premature adrenarche, hypercortisolism or prolonged glucocorticoid exposure may be more likely to develop central adiposity, impaired glucose tolerance, hypertension or reduced quality of life. Follow-up should therefore include blood pressure, glucose metabolism, psychosocial well-being, physical activity and treatment adherence. High-quality pediatric adrenal endocrinology does not measure steroids alone, but also prevents metabolic and functional outcomes that gradually develop over the years of growth.

Transition to adult care is particularly delicate for patients with chronic adrenal disorders. Adolescence and early adulthood are periods in which the risk of discontinuing care, reduced adherence, inadequate independent management of stress dosing and loss to follow-up increases. This is especially relevant for CAH, adrenal insufficiency, hereditary PPGL and tumor predisposition syndromes. Transition should not be a simple administrative transfer, but a structured pathway through which the young patient progressively acquires practical skills, knowledge of the disorder and the ability to manage emergencies and daily treatment.

Long-term follow-up depends on the etiology. In patients with adrenal insufficiency, the priorities are safety, prevention of crises and adequate replacement; in CAH, the focus is on androgen control, future fertility and treatment-related complications; in adrenal tumors or PPGL, follow-up extends to oncological and genetic surveillance. Despite these differences, a common principle remains: patients must be accompanied throughout development, recognizing that an endocrine disorder originating in childhood may have clinical, metabolic and psychological consequences extending over decades.

In conclusion, discussing the adrenal glands in childhood means discussing developmental endocrinology. Good management does not consist solely of correcting a hormonal defect, but of protecting growth, maturation, autonomy and future health. Follow-up must therefore be continuous, individualized and based on a broad perspective in which the adrenal gland is understood not as an isolated organ, but as an integral component of the child's biological trajectory toward adulthood.